LNSRHIGH SIGNALRISK10-K

LNSR's financial condition deteriorated dramatically with stockholders' equity plunging into negative territory at -$26.0M while operating losses more than doubled and a failed merger created significant new litigation and business risks.

The company's equity turning negative by over $30M combined with operating cash flow deteriorating by 552% signals severe financial distress that threatens the company's viability. The terminated merger agreement has introduced material new risks including potential shareholder litigation and adverse impacts on business operations, while the company burns through cash at an accelerating rate.

Comparing 2026-03-31 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

LNSR experienced severe financial deterioration across all key metrics, with stockholders' equity collapsing from $4.9M to negative $26.0M, operating losses widening from $10.7M to $24.6M, and operating cash flow burning accelerating to $14.8M from $2.3M. The company built inventory significantly (+88%) while current liabilities spiked 170% and cash reserves declined 20%, creating a dangerous liquidity profile. This constellation of worsening profitability, cash burn, and balance sheet strength suggests the company faces mounting financial distress that could threaten its going concern status.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-635.2%
$4.9M→-$26.0M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Cash Flow
Cash Flow
-551.9%
-$2.3M→-$14.8M

Operating cash flow fell 551.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
+170.4%
$15.0M→$40.6M

Current liabilities surged 170.4% — significant near-term obligations; verify ability to meet short-term debt.

Operating Income
P&L
-130.5%
-$10.7M→-$24.6M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Inventory
Balance Sheet
+88.3%
$11.4M→$21.5M

Inventory surged 88.3% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Total Liabilities
Balance Sheet
+75.6%
$47.7M→$83.7M

Liabilities grew 75.6% — significant increase in debt or obligations, assess impact on financial flexibility.

SG&A Expense
P&L
+70.5%
$26.5M→$45.2M

SG&A up 70.5% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Capital Expenditure
Cash Flow
-46.8%
$156K→$83K

Capex reduced 46.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Interest Expense
P&L
-33%
$2.0M→$1.3M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
-20.2%
$16.3M→$13.0M

Cash decreased 20.2% — monitor burn rate and upcoming capital needs.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-02-27
ADDED
As of February 28, 2026, there were 12,095,631 shares of the registrant s common stock outstanding.
The principal risks and uncertainties affecting our business include the following: The announcement of the termination of the Merger Agreement could negatively impact our business, financial condition, results of operations or our stock price.
We may experience shareholder litigation related to the termination of the Merger Agreement, which could result in payment of damages.
Our results have been in the past, and could be in the future, adversely affected by economic uncertainty or deteriorations in economic conditions.
Food and Drug Administration, or FDA, in June 2022, and we executed a controlled and targeted initial launch of the ALLY System in August 2022.
+7 more — sign up free →
REMOVED
As of January 31, 2025, there were 11,789,492 shares of the registrant s common stock outstanding.
The principal risks and uncertainties affecting our business include the following: Our results have been in the past, and could be in the future, adversely affected by economic uncertainty or deteriorations in economic conditions.
Food and Drug Administration, or FDA, in June 2022, and we began commercialization of the ALLY System in August 2022.
In 2024, we obtained certification of our ALLY System under the Medical Devices Regulation in the European Union, or EU, and we have also received regulatory clearance in India, Taiwan, and certain other countries.
In addition, we are pursuing additional marketing or certification applications through our distributors in South Korea and China.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →